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Editorial Comment 
Myocardial Stunning in 
Hypertrophic Cardiomyopathy?* 
ANDR6 PASTERNAC, MD, FACC 
Myocardial perfusion abnormalities occur commonly in pa- 
tients with hypertrophic cardiomyopathy presenting with or 
without angina and with or without dysfunction (l-5). 
O’Gara et al. (5) identified regional perfusion defects after 
maximal exercise in 57% of patients. The majority of the 
patients had a reversible defect; a fixed defect was observed 
predominantly in patients with depressed left ventricular 
function at rest. Correlatively. a spectrum of left ventricular 
wall motion abnormalities ranging from abnormal left ven- 
tricular diastolic mechanics (6) to segmental systolic abnor- 
malities (7) and transmural myocardial infarction (8), often 
silent. has been reported in patients with hypertrophic 
cardiomyopathy and normal coronary arteries. These abnor- 
malities may lead, although infrequently, to progression into 
a segmental or generalized hypokinetic left ventricle, with 
ventricular dilation and heart failure (7-10). 
Current study. In this issue of the Journal, Fine and 
coworkers (1 I) report the history of a young woman with 
mildly obstructive hypertrophic cardiomyopathy presenting 
with chest pain, electrocardiographic abnormalities sugges- 
tive of myocardial infarction and evidence of an apical 
aneurysm by echocardiography, radionuclide and contrast 
ventriculography in the presence of normal coronary arter- 
ies. Verapamil therapy was started, and 13 days after admis- 
sion single photon emission computed tomographic imaging 
(SPECT) revealed normal perfusion of the area shown to be 
aneurysmal 5 days earlier. In the following weeks, ventric- 
ular contraction returned progressively to normal. The au- 
thors suggest that the reversibility of the wall motion abnor- 
mality with the relief of ischemia might be predicted by 
SPECT scintigraphy. Thus, this study documents that re- 
versible systolic wall motion abnormalities do occur in 
patients with hypertrophic cardiomyopathy concomitant 
with transient severe regional ischemia. In addition, sequen- 
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tial echocardiograms showed the persistence of wall motion 
abnormalities after the normalization of myocardial perfu- 
sion with delayed but complete functional recovery; this 
truly represents “myocardial stunning” (12). However, the 
lack of simultaneous assessment of myocardial perfusion 
and of left ventricular wall dynamics as well as the absence 
of sequential evaluation of myocardial perfusion may limit 
the validity of these conclusions. Thus, it would have been 
helpful to obtain an at rest thallium SPECT study on 
admission when the patient was symptomatic; we can pre- 
sume that it would have shown a regional perfusion defect in 
the aneurysmal area. 
The normalcy of the (at rest ?) SPECT study done on the 
13th day after admission on verapamil therapy implies that in 
the area of the apical dysfunction observed on admission 
there was now adequately perfused and viable tissue sug- 
gesting a favorable functional prognosis. Although no wall 
motion study was done at the time of the normal thallium 
imaging, some regression of the apical dysfunction would 
probably have been apparent. A recent study by Stratton et 
al. (13) in patients with prior myocardial infarction has 
addressed the issue of the correlation between regional wall 
motion abnormalities and the severity of the tomographic 
thallium perfusion defects. Overall, there was an excellent 
correlation. but discrepancies were noted and wall motion 
abnormalities affected more of the ventricle than did perfu- 
sion abnormalities. Thus, among regions with no defect or a 
very small defect, 6% demonstrated echocardiographic aki- 
nesia or dyskinesia, or both. The explanation for the discrep- 
ancy remains unclear. Similarly, Massie et al. (14) noted that 
11% of regions with normal thallium uptake had abnormal 
wall motion. Indeed. it would have been helpful to repeat the 
thallium study at 6 weeks after hospital discharge, when 
there was resolution of the wall motion abnormalities to 
document whether subtle change in thallium kinetics had not 
occurred when compared with the “normal” thallium perfu- 
sion-in particular, in the early acquisitions. 
Significance of myocardial ischemia and myocardial stun- 
ning in patients with hypertrophic cardiomyopathy. The vul- 
nerability to myocardial ischemia in patients with hypertro- 
phic cardiomyopathy has been well documented by coronary 
flow studies showing a reduced myocardial perfusion for unit 
left ventricular mass and increased coronary resistance at 
rest (IS. 16) with inadequate coronary reserve during pacing 
stress (17,181. This chronic hypoperfusion may result in 
progressive impairment of ventricular function, in particular 
subendocardial, and may cause focal necrosis and fibrosis. 
In contrast, “myocardial stunning” (12,19) results from an 
acute and transient ischemic event but it may persist for 
weeks after the restoration of adequate myocardial perfusion 
with eventual recovery to normal function. This has been 
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reported in experimental models of brief transient periods of 
coronary occlusion followed by reperfusion (20), at?d in 
clinical settings of transient ischemia induced by exercise or 
by coronary angioplasty (21) and in patients after reperfusion 
for acute myocardial infarction (22). Such abnormalities of 
myocardial contraction may occur more frequently than 
realized in hypertrophic cardiomyopathy because it is pos- 
sible to induce silent myocardial ischemia with exercise in 
asymptomatic patients with this condition (23). 
sient, spontaneous regional ischemia in hypertrophic cardio- 
myopathy remains to be elucidated, and further studies will 
be necessary to assess the role of prophylactic calcium 
antagonist therapy (37) in preventing ischemic alterations of 
myocardial function. 
I thank Dr. Jean Gregoire from the Department of Nuclear Medicine, 
Montreal Heart Institute, for his comments and suggestions. 
The mechanism of these spontaneous transient episodes 
of myocardial ischemia remains unclear. Along with the 
potential causes listed by Fine et al. (1 l), the role of dynamic 
alterations in the myocardial microcirculation must be con- 
sidered (24) possibly modulated by catecholamines (25). In 
fact, coronary spasm, at the epicardial or arteriolar level, 
would constitute a clear clinical replication of the experi- 
mental settings of “myocardial stunning.” The clinical epi- 
sode induced by methylergonovine is consistent with this 
hypothesis. Clearly, several mechanisms may be operative 
here. The abnormality of calcium fluxes and calcium- 
antagonist receptors, possibly genetic, recently demon- 
strated in patients with hypertrophic cardiomyopathy (26), 
may affect not only cardiac tissue but also coronary and 
peripheral vascular smooth muscles (27,28) and may help to 
better understand the pathophysiology of ischemia and its 
therapy. Indeed, the efficacy of verapamil in improving 
myocardial function in this patient is noteworthy. In addition 
to its role in arterial (29) and arteriolar (24) spasm, verapamil 
improves relaxation and diastolic filling (30,31) and has been 
shown to diminish inducible silent ischemia in many asymp- 
tomatic patients with hypertrophic cardiomyopathy (23). It 
appears to be the most effective of the many drugs adminis- 
tered to the cardiomyopathic hamsters (32,33); it may pro- 
tect against myocardial damage by inhibiting voltage- 
dependent calcium uptake and preventing free radical- 
generated lipid peroxidation and cell injury (34). 
Furthermore, in the experimental setting of “myocardial 
stunning,” it has recently been shown to enhance the 
postischemic functional and metabolic recovery (35), in 
particular in left ventricular hypertrophy (36), by diminishing 
minimal coronary resistance and reducing or preventing the 
alterations in high energy metabolism. 
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